# Industry relations with RIs

Anna Sandström, Director Science Policy and Relations Europe, AstraZeneca

28 October 2020



# Our global R&D centres




In 2019, AstraZeneca invested $6.1bn in R&D

A collaborative R&D climate is imperative to attract R&D investments

Research infrastructures are important platforms for fruitful collaborations

# More than 1,400 active collaborations in 2020

Keeping doors and minds open




Joint research centres with academia

Innovating with biotech

Partnering with industry

# Crystallography Nobel Prizes

**1962** Globular proteins



**1964** Vitamin B



**1997** ATP-ase



**2003** Ion channels




**2009** Ribosome



**2006** Eukaryotic transcription



**1962** DNA



**2012** GPCR



**1988** Photosynthetic reaction centre



# Use of synchrotrons in future drug discovery and development



Protein structure elucidation will continue to be core to drug discovery

Formulation as well as understanding and developing drug delivery vehicles



Advanced imaging of cells, tissue, organs and organisms

# Maximising impact to tackle societal challenges

- Routine measurements 'fee for service'
- R&D collaborations:
  - Jointly answering challenging research questions
  - Co-creation to develop new methodologies

**Dialogue** – outreach activities as well as discussions with advanced users on e.g. interfaces/instrumentation

**Competence** – resources and ability to co-develop new technologies and experiments as well as to train, counsel and support industrial users

**Funding** – incentivizing a collaborative climate